Home > Riviste > Minerva Biotecnologica > Fascicoli precedenti > Minerva Biotecnologica 1999 Dicembre;11(4) > Minerva Biotecnologica 1999 Dicembre;11(4):261-70

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Estratti

MINERVA BIOTECNOLOGICA

Rivista di Biologia Molecolare e Biotecnologie


Indexed/Abstracted in: EMBASE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,246


eTOC

 

  TUMOR IMMUNOLOGY


Minerva Biotecnologica 1999 Dicembre;11(4):261-70

lingua: Inglese

Presentation of ­tumor anti­gens. The ­role of den­drit­ic ­cells

Paglia P., Colombo M. P.

mmunotherapy and Gene Therapy Unit, Istituto Nazionale Tumori, Milano, Italy


FULL TEXT  


Human ­tumors ­express a num­ber of pro­tein anti­gens ­that can be rec­og­nized by T ­cells, ­thus pro­vid­ing poten­tial tar­gets for can­cer immu­no­ther­a­py. Dendritic ­cells are ­rare leu­ko­cytes ­that are unique­ly ­potent in ­their abil­ity to ­present anti­gens to T ­cells, and ­this prop­er­ty has prompt­ed ­their ­recent appli­ca­tion to ther­a­peu­tic can­cer vac­cines. Isolated den­drit­ic ­cells load­ed ­with ­tumor anti­gen ex ­vivo and admin­is­tered as a cel­lu­lar vac­cine ­have ­been ­found to ­induce pro­tec­tive and ther­a­peu­tic ­anti-­tumor immu­nity in experi­men­tal ani­mals. In ­pilot clin­i­cal ­trials of den­drit­ic ­cells vac­ci­na­tion for ­patients ­with non-Hodgkints lym­pho­ma and mel­a­no­ma, induc­tion of ­anti-­tumor ­immune respons­es and ­tumor regres­sions ­have ­been ­observed. Additional ­trials of den­drit­ic ­cells vac­ci­na­tion for a varie­ty of ­human can­cers are ­under- way, and meth­ods for tar­get­ing ­tumor anti­gens to den­drit­ic ­cells in ­vivo are ­also ­being ­explored. Exploitation of the anti­gen-pre­sent­ing prop­er­ties of den­drit­ic ­cells ­thus ­offers prom­ise for the devel­op­ment of effec­tive can­cer immu­noth­e­ra­pies.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail